Dyne Therapeutics (DYN) CMO Douglas Kerr Sells 1,556 Shares

What Happened
Douglas Kerr, Chief Medical Officer of Dyne Therapeutics (DYN), sold 1,556 shares on 2026-08-13 in an automatic sale to satisfy tax withholding related to the vesting of restricted stock units. The weighted-average sale price was $26.28 per share (range $26.17–$26.39), for total proceeds of approximately $40,892. The sale was conducted under the RSU agreement and was not a discretionary trade by the reporting person.

Key Details

• Transaction date: 2026-08-13 (Filed on Form 4: 2026-08-17 — timely filing).
• Transaction type/code: Sale (S); 1,556 shares disposed.
• Price: Weighted average $26.28; trades occurred between $26.17 and $26.39 (see footnote F2).
• Total proceeds: ~$40,892.
• Reason/footnote: Automatic sale to satisfy tax withholding on vested RSUs per RSU agreement; treated as a binding contract and not a discretionary trade (footnote F1).
• Holdings note: Reporting person’s position includes 140,001 unvested RSUs (footnote F3).
• Additional: The filer offers to provide a breakdown of the number of shares sold at each separate price within the reported range upon request (footnote F2).

Context
Tax-withholding sales tied to RSU vesting are routine administrative transactions and generally do not signal a change in an insider’s view of the company. Purchases are typically more informative about insider sentiment; this sale appears to be a non-discretionary, tax-related disposition.